Advertisement

CYP2B6, ABCB1 and OPRM1 profile in a stillborn affected by chronic methadone intoxication

  • Eva MontanariEmail author
  • Maria Paola Bonasoni
  • Federica Alessandrini
  • Raffaele Frazzi
  • Federico Mocchegiani
  • Francesco Paolo Busardò
  • Raffaele Giorgetti
  • Adriano Tagliabracci
Letter to the Editor

Dear Editor,

The indirect effect of maternal drug exposure on the fetus may include serious consequences such as neonatal abstinence syndrome or, more rarely, intrauterine fetal death (IUFD).

Kalin [1] reported the incidence of fetal drug exposure in 39 of 58 fetal/neonatal deaths among a total of 23,400 general fatalities; notably, only 39 of the cases provided toxicological analyses. Toxicological analyses showed positive results in 22 of 39 cases (17/39 had negative toxicological results). In only 2/22 cases, IUFD was attributed to drug intoxication, as high levels of methamphetamine (1200–1500 ng/mL) were detected in fetal blood. In the other 20 cases, drug was detected in such a small amount that it was considered an occasional finding; the main causes of death were placental abruption/prematurity/stillbirth in 13 cases, maternal drug abuse associated with fetal asphyxia in two cases, chorioamnionitis in one case, drowning in one case, car accident in one case and undetermined in...

Notes

Compliance with ethical standards

Conflict of interest

The authors have no financial or other relations that could lead to a conflict of interest.

Ethical approval

In Italy, there is no legislation that forbids the use of human tissues collected during an autopsy, provided that the samples are made anonymous and linked exclusively to codes. We followed this privacy-guaranteed principle. The mother was not traceable, and it was not possible to obtain her consent.

References

  1. 1.
    Kalin JR (2014) Incidence of fetal drug exposure in Alabama: 2004–2011. J Forensic Sci 59:1029–1035CrossRefGoogle Scholar
  2. 2.
    Montanari E, Bonasoni MP, Licata M, Salomone A, Gerace E, Vivarelli M, Giorgetti R, Tagliabracci A (2018) Toxicological and histological analyses for a stillborn delivered by a mother under methadone maintenance therapy. Forensic Toxicol 36:514–524CrossRefGoogle Scholar
  3. 3.
    Newman RG, Bashkow S, Calko D (1975) Results of 313 consecutive live births of infants delivered to patients in the New York City Methadone Maintenance Treatment Program. Am J Obstet Gynecol 121:233–237CrossRefGoogle Scholar
  4. 4.
    Archie CL, Lee MI, Sokol RJ, Norman G (1989) The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 74:254–255Google Scholar
  5. 5.
    Crettol S, Déglon J-J, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604CrossRefGoogle Scholar
  6. 6.
    Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, Eap CB (2013) Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics 23:84–93CrossRefGoogle Scholar
  7. 7.
    Fonseca F, de la Torre R, Diaz L, Pastor A, Cuyas E, Pizarro N, Khymenets O, Farre M, Torrens M (2011) Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 6:e19527.  https://doi.org/10.1371/journal.pone.0019537 (open access article) CrossRefGoogle Scholar
  8. 8.
    Gadel S, Crafford A, Regina K, Kharasch ED (2013) Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Drug Metab Dispos 41:709–713CrossRefGoogle Scholar
  9. 9.
    Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, Lane HY (2011) Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12:1525–1533CrossRefGoogle Scholar
  10. 10.
    Kharasch ED, Regina KJ, Blood J, Friedel C (2015) Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology 123:1142–1153CrossRefGoogle Scholar
  11. 11.
    Kharasch ED, Stubbert K (2013) Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol 53:305–313CrossRefGoogle Scholar
  12. 12.
    Kringen MK, Chalabianloo F, Bernard J-P, Bramness J, Molden E, Høiseth G (2017) Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment. Ther Drug Monit 39:550–555CrossRefGoogle Scholar
  13. 13.
    Lee H-Y, Li J-H, Sheu Y-L, Tang H-P, Chang W-C, Tang T-C, Yeh Y-C, Wang S-Y, Liu R-H (2013) Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan. Biomed Res Int 2013:741403.  https://doi.org/10.1155/2013/741403 (open access article) Google Scholar
  14. 14.
    Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ (2013) CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 18:709–716CrossRefGoogle Scholar
  15. 15.
    Wang S-C, Ho I-K, Tsou H-H, Tian J-N, Hsiao C-F, Chen C-H, Tan H, Lin L, Wu C-S, Su L-W, Huang C-L, Yang Y-H, Liu M-L, Lin K-M, Chen C-Y, Liu S, Wu H-Y, Chan H-W, Tsai M-H, Lin P-S, Liu Y-L (2011) CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 31:463–469CrossRefGoogle Scholar
  16. 16.
    Ahmad T, Valentovic MA, Rankin GO (2018) Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol 153:196–204CrossRefGoogle Scholar
  17. 17.
    Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D (2010) OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 88:383–389CrossRefGoogle Scholar
  18. 18.
    Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D (2011) Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations. J Anal Toxicol 35:431–437CrossRefGoogle Scholar
  19. 19.
    Christoffersen DJ, Damkier P, Feddersen S, Moller S, Thomsen JL, Brasch-Andersen C, Brøsen K (2016) The ABCB1, rs9282564, AG and TT genotypes and the COMT, rs4680, AA genotype are less frequent in deceased patients with opioid addiction than in living patients with opioid addiction. Basic Clin Pharmacol Toxicol 119:381–388CrossRefGoogle Scholar
  20. 20.
    Madadi P, Kelly LE, Ross CJ, Kepron C, Edwards JN, Koren G (2016) Forensic investigation of methadone concentrations in deceased breastfed infants. J Forensic Sci 61:576–580CrossRefGoogle Scholar
  21. 21.
    Walter C, Lötsch J (2009) Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146:270–275CrossRefGoogle Scholar
  22. 22.
    Haerian BS, Haerian MS (2013) OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics 14:813–824CrossRefGoogle Scholar
  23. 23.
    Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G, Schmidt PH, Lötsch J (2009) A common human µ-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 284:6530–6535CrossRefGoogle Scholar
  24. 24.
    Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA (2012) ABCB1 haplotype and OPRM1 118A>G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med 5:53–62.  https://doi.org/10.2147/PGPM.S29272 (open access article) Google Scholar
  25. 25.
    Maurer HH (1999) Systematic toxicological analysis procedures for acidic drugs and/or metabolites relevant to clinical and forensic toxicology and/or doping control. J Chromatogr B 733:3–25CrossRefGoogle Scholar
  26. 26.
    Li Y, Kantelip J-P, Gerritsen-van Schieveen P, Davani S (2008) Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 12:109–124CrossRefGoogle Scholar
  27. 27.
    Ahmad T, Sabet S, Primerano DA, Richards-Waugh LL, Rankin GO (2017) Tell-tale SNPs: the role of CYP2B6 in methadone fatalities. J Anal Toxicol 41:325–333CrossRefGoogle Scholar
  28. 28.
    Crettol S, Deglon J-J, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668–681CrossRefGoogle Scholar
  29. 29.
    Levran O, O’Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17:2219–2227CrossRefGoogle Scholar
  30. 30.
    Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R (2016) Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse 42:587–596CrossRefGoogle Scholar
  31. 31.
    Kong X, Deng H, Alston T, Kong Y, Wang J (2017) Association of opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with nicotine dependence. Oncotarget 8:84329–84337.  https://doi.org/10.18632/oncotarget.20939 (open access article) Google Scholar
  32. 32.
    Kong X, Deng H, Gong S, Alston T, Kong Y, Wang J (2017) Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies. BMC Med Genet 18:120.  https://doi.org/10.1186/a12881-017-0478-4 (open access article) CrossRefGoogle Scholar
  33. 33.
    Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16:809–817CrossRefGoogle Scholar
  34. 34.
    Manini AF, Jacobs MM, Vlahov D, Hurd YL (2013) Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. J Med Toxicol 9:148–154CrossRefGoogle Scholar
  35. 35.
    Wang L, Wei C, Xiao F, Chang X, Zhang Y (2019) Influences of COMT rs4680 and OPRM1 rs1799971 polymorphisms on chronic postsurgical pain, acute pain, and analgesic consumption after elective cesarean delivery. Clin J Pain 35:31–36CrossRefGoogle Scholar

Copyright information

© Japanese Association of Forensic Toxicology 2019

Authors and Affiliations

  • Eva Montanari
    • 1
    Email author
  • Maria Paola Bonasoni
    • 2
  • Federica Alessandrini
    • 1
  • Raffaele Frazzi
    • 3
  • Federico Mocchegiani
    • 4
  • Francesco Paolo Busardò
    • 1
  • Raffaele Giorgetti
    • 1
  • Adriano Tagliabracci
    • 1
  1. 1.Section of Legal Medicine, Department of Excellence of Biomedical Sciences and Public HealthPolytechnic University of MarcheAnconaItaly
  2. 2.Pathology UnitAzienda Unità Sanitaria Locale-IRCCS di Reggio EmiliaReggio EmiliaItaly
  3. 3.Laboratory of Translational ResearchAzienda Unità Sanitaria Locale-IRCCS di Reggio EmiliaReggio EmiliaItaly
  4. 4.Hepatopancreatobiliary and Transplantation Surgery Unit, Experimental and Clinical Medicine DepartmentPolytechnic University of MarcheAnconaItaly

Personalised recommendations